Affimed N.V. is a clinical-stage biopharmaceutical company developing cancer immunotherapies. Lead product candidates include AFM13 for CD30-positive lymphoma, AFM24 for advanced cancers, and AFM28 for acute myeloid leukemia. AFM32 is another ICE candidate in preclinical development for solid tumors. The company has collaborations with Artiva Biotherapeutics, Roivant Sciences Ltd., and Genentech. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 0.3 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 0.3 |